KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Other Operating Expenses (2016 - 2025)

NovoCure's Other Operating Expenses history spans 11 years, with the latest figure at $68.7 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 1.85% year-over-year to $68.7 million; the TTM value through Dec 2025 reached $240.1 million, changed 0.42%, while the annual FY2025 figure was $240.1 million, 0.42% changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $68.7 million at NovoCure, up from $58.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $68.7 million in Q4 2025 and bottomed at $31.4 million in Q1 2021.
  • The 5-year median for Other Operating Expenses is $55.5 million (2024), against an average of $50.8 million.
  • The largest annual shift saw Other Operating Expenses skyrocketed 40.03% in 2023 before it decreased 3.2% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $39.0 million in 2021, then grew by 27.31% to $49.6 million in 2022, then grew by 19.26% to $59.2 million in 2023, then rose by 13.89% to $67.4 million in 2024, then grew by 1.85% to $68.7 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Other Operating Expenses are $68.7 million (Q4 2025), $58.5 million (Q3 2025), and $57.1 million (Q2 2025).